Last reviewed · How we verify
Analogous GnRH antagonist
This GnRH antagonist blocks gonadotropin-releasing hormone receptors to suppress luteinizing hormone and follicle-stimulating hormone, reducing sex hormone production.
This GnRH antagonist blocks gonadotropin-releasing hormone receptors to suppress luteinizing hormone and follicle-stimulating hormone, reducing sex hormone production. Used for Advanced prostate cancer (hormone-sensitive), Hormone-dependent breast cancer, Endometriosis.
At a glance
| Generic name | Analogous GnRH antagonist |
|---|---|
| Also known as | Cetrotide® |
| Sponsor | Merck KGaA, Darmstadt, Germany |
| Drug class | GnRH antagonist |
| Target | GnRH receptor (GnRHR) |
| Modality | Small molecule |
| Therapeutic area | Oncology; Reproductive/Endocrinology |
| Phase | Phase 2 |
Mechanism of action
GnRH antagonists directly bind to and inhibit GnRH receptors on pituitary gonadotroph cells, preventing the release of LH and FSH without an initial flare effect (unlike GnRH agonists). This leads to rapid suppression of testosterone in males and estrogen in females, making them useful for hormone-dependent conditions. The antagonist mechanism provides faster onset of action and avoids the transient hormone surge seen with agonists.
Approved indications
- Advanced prostate cancer (hormone-sensitive)
- Hormone-dependent breast cancer
- Endometriosis
- Uterine fibroids
Common side effects
- Hot flashes
- Decreased libido
- Erectile dysfunction
- Injection site reactions
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Analogous GnRH antagonist CI brief — competitive landscape report
- Analogous GnRH antagonist updates RSS · CI watch RSS
- Merck KGaA, Darmstadt, Germany portfolio CI